Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Abstract Background Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-cohort, dose-escalation, phase I...

Full description

Bibliographic Details
Main Authors: Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers
Format: Article
Language:English
Published: BMJ Publishing Group 2018-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Metastatic renal cell carcinoma
Nivolumab
Immune checkpoint inhibitor
Sunitinib
Pazopanib
Antiangiogenic
Online Access:http://link.springer.com/article/10.1186/s40425-018-0420-0

Internet

http://link.springer.com/article/10.1186/s40425-018-0420-0

Similar Items